Lumos Pharma, Inc. (LUMO)
After hours:
| Previous close | 2.8700 |
| Open | 2.7600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.7302 - 3.0700 |
| 52-week range | 2.4100 - 4.5500 |
| Volume | |
| Avg. volume | 23,649 |
| Market cap | 24.512M |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.1800 |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.50 |
GlobeNewswireLumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe. Pediatric Endocrine Society (PES) Annual Meeting, held May 2-5, 2024, in Chicago, IL Abstra
- GlobeNewswire
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that on Thursday, March 14, 2024, the Company received a Notice of Allowance from the US Patent and Trade Office (USPTO) for claims in its patent application number PCT/US22/050700 titled “Compactable Oral Formulations of Ibutamoren.” This patent contains cl
Simply Wall St.Lumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Lumos Pharma ( NASDAQ:LUMO ) Full Year 2023 Results Key Financial Results Net loss: US$34.0m (loss widened by 9.6% from...
